Scholz: Billions in investment by US pharma company Lily is a sign
The US company is building a new factory in Germany. Chancellor Scholz described this as a “pleasing sign” of Germany’s industrial appeal.
Alzey (dpa/d.de) - German Chancellor Olaf Scholz has described the billions of euros in investment by the US pharmaceuticals company Eli Lilly as “a pleasing sign of Germany’s appeal as a location for pharmaceuticals and industry”. The company is investing around 2.3 billion euros in building a new factory in Alzey in Rhineland-Palatinate. “We are talking about one of, if not the biggest single investment in Germany as a pharmaceuticals location since reunification,” Scholz said at the symbolic ground-breaking ceremony.
Eli Lilly will be building a facility in Alzey for the production of injectable medicines. Construction is scheduled to begin in the summer. According to the company, the plant is due to go into operation in 2027 and employ a workforce of up to 1,000 people. No subsidies were granted for the project.
Scholz made reference to other investments by pharma companies in Germany. As far as patent registrations in the area of health were concerned, Germany was second only to the USA, stressed the chancellor. The German government wants to further improve the framework conditions with a new pharma strategy.